Sainbainuu International Ltd., a Chinese-based bio-pharmaceuticals and health products distribution company, and USA Pharmaceuticals, a nutraceutical company announced a strategic partnership today that will aid with the Diabetes epidemic in China. According to a New England Journal of Medicine Report, nearly 92 Million Adults in China have Diabetes which represents almost 1 in 10.
The therapy will address the apparent causes of diabetes, including low immune function, beta cell failure, blood system damage, and peripheral neuropathy, as described in the “Four-Pathogenic Theory,” published in the American Journal of Medicine in June 2008.
This new combination therapy is a “bidirectional polymerization healing treatment,” (BPHT) addressing the problem of diabetes in two ways. First, it aims to improve immune system function and reduce chronic bacterial inflammation. Second, it seeks to improve and repair islet function, reduce stimulation and damage to the pancreatic islet, and control beta cell apoptosis, promoting beta cell regeneration.
After more than 10 years of research and development by USA Pharmaceuticals cooperating with Thomas Lahey and other scientists, the diabetes healing product “U Metron” based on the “bidirectional polymerization healing treatment,” will be on the market.
The goal of the therapy is to provide a safe, effective alternative to insulin therapy and biguanide drugs and to reduce complications for the diabetes patients in China.
ABOUT SAINBAINUU INTL, LTD.
Founded in 1995, Sainbainuu Intl is an integrated modern enterprise that contains biological pharmaceutical, scientific research, health product sales, health service center chain and health knowledge promotion. Since its move to Beijing in 2006, the company has scaled doubling its revenue in the last 4 years. It now has 9 large regional divisions, 37 support service centers and over 200 gold level service networks. Its mission is dedicated to providing highly sophisticated products and quality service for middle-aged and seniors with a strong emphasis on chronically diseased patients.
No comments:
Post a Comment